Co-Diagnostics, Inc. (CODX)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 2
Do Nothing: fundamentalScore is 1 (below required floor of 3); strategy requires fundamentalScore >= 3 before any bullish entry. Separately, the chart only scores 2 out of 5, with price below the 20-day and 200-day averages, below EMA9 and EMA21, under VWAP, and with a negative MACD histogram.
Company overview
Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company specializing in the design, production, and marketing of reagents for nucleic acid testing. Their products include the Co-Dx PCR platform, offering PCR diagnostic tests for various diseases and applications in human health, mosquito pathogen screening, and agriculture. Founded in 2013, the company is based in Salt Lake City, Utah.
Fundamental
very weakCODX faces substantial going-concern risks with severe revenue decline and heavy cash burn.
SEC filings (10-K filed 2026-03-31; 10-Q filed 2026-05-14) include “substantial doubt” going-concern language amid continued losses and reliance on external financing. Revenue fell to $0.62M in FY2025 (down from $97.89M in FY2021) and cash burn remains heavy (FY2025 operating cash flow -$29.14M; Q1 2026 operating cash use -$7.8M). A May 2026 8-K press release announced a ~$3.0M private placement with warrants, underscoring dilution risk. Despite low debt and a DCF output above the current price, the near-term solvency/dilution profile drives a high-risk (score 1) assessment.
Sentiment
very weakSentiment is dominated by liquidity and financing risks, with no actionable catalysts identified.
Last ~14d media tone is mildly positive and PR-driven (Mexico distributor agreement), improving vs a mixed 30–90d baseline, but there are no clearly actionable 1–30d catalysts from official PRs. Red-Flag Screen triggered a severe cap (going-concern/substantial doubt language in recent SEC filings per upstream stage), so the qualitative score is capped at 1.
Technical
weakCODX is oversold but remains below key trend measures with fading momentum.
CODX still screens liquid on a 20-day lookback because of the late-May spike, but the current tape has not repaired. The 3.33 close sits above only the 50-day SMA 3.18 and below SMA20 5.53, SMA200 6.37, EMA9 4.36, EMA21 4.52, and daily VWAP 3.37. Williams %R is deeply oversold at -96.41, yet RSI14 44.41, a negative MACD histogram of -0.43, and ADX14 30.77 argue this is still a forceful pullback rather than a confirmed bullish swing.
You’re looking at 2026-06-17 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.